US Cell and Gene Therapy Market Demand, Size, and Growth Rate Forecast 2035
According to Payal Rabde, who specializes in the development and commercialization of CAR-T cell therapies and gene editing technologies, with 4+ years of experience in market research and industry analysis, extensive research indicates strong growth opportunities in the U.S. cell and gene therapy market. The global U.S. cell and gene therapy market size was estimated at USD 4.09 billion in 2025 and is predicted to increase from USD 4.74 billion in 2026 to approximately USD 20 billion by 2035, expanding at a CAGR of 17.2% from 2026 to 2035. Her analysis highlights the increasing adoption of personalized cell and gene therapies, CAR-T cell therapies, gene editing technologies, viral and non-viral gene delivery systems, automated cell manufacturing platforms, and regenerative medicine approaches. The research also examines the competitive strategies of key industry participants, including, Novartis AG, Bristol Myers Squibb, Bluebird Bio, Sarepta Therapeutics, BioMarin Pharamceutical, Beam Therapeutics, and Editas Medicine, shaping the future by expanding allogenic cell therapy platforms, integrating AI-driven therapy design and manufacturing, strengthening scalable and automated bioprocessing, accelerating in vivo gene delivery innovation and broadening regenerative medicine application in the global U.S. cell and gene therapy market.
Last Updated : 21 July 2026
Category: Therapeutic Area
Insight Code: 6852
Format: PDF / PPT / Excel